Explore more publications!
Bahamas STEM News
Got News to Share?

Bahamas STEM News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bahamas STEM News.

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

Press releases published on March 25, 2026

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
35 minutes ago

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Indeterminate GlobeNewswire
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
36 minutes ago

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204

Indeterminate GlobeNewswire
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
36 minutes ago

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

Indeterminate GlobeNewswire
STS Digital Unveils First-to-Market Structured Products Platform, Partnering with Kraken
an hour ago

STS Digital Unveils First-to-Market Structured Products Platform, Partnering with Kraken

Indeterminate GlobeNewswire
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
an hour ago

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Indeterminate GlobeNewswire
Verano to Report First Quarter 2026 Financial Results on April 30, 2026
an hour ago

Verano to Report First Quarter 2026 Financial Results on April 30, 2026

Indeterminate GlobeNewswire
Energous Wireless Power Solutions Reports Fiscal Year 2025 Results
an hour ago

Energous Wireless Power Solutions Reports Fiscal Year 2025 Results

Indeterminate GlobeNewswire
Notch Raises $30 Million to Bring Production-Ready AI Agents to Regulated Industries
an hour ago

Notch Raises $30 Million to Bring Production-Ready AI Agents to Regulated Industries

Indeterminate GlobeNewswire
Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026
an hour ago

Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026

Indeterminate GlobeNewswire
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)
an hour ago

Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)

Indeterminate GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
an hour ago

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Indeterminate GlobeNewswire
Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval
an hour ago

Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval

Indeterminate GlobeNewswire
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
an hour ago

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Indeterminate GlobeNewswire
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
an hour ago

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Indeterminate GlobeNewswire
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
an hour ago

Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.

Indeterminate GlobeNewswire
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
an hour ago

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Indeterminate GlobeNewswire
Wowza's Elliot Miller Joins Colorado PBS12 Board of Directors
an hour ago

Wowza's Elliot Miller Joins Colorado PBS12 Board of Directors

Indeterminate GlobeNewswire
ADMA Biologics Addresses Misleading Short-Seller Report
2 hours ago

ADMA Biologics Addresses Misleading Short-Seller Report

Indeterminate GlobeNewswire
BOSS Zhipin Continues Share Repurchase Program; Cumulative Repurchases Reach Nearly RMB450 Million in FY26
2 hours ago

BOSS Zhipin Continues Share Repurchase Program; Cumulative Repurchases Reach Nearly RMB450 Million in FY26

Indeterminate GlobeNewswire
ZenoWell Announces Strategic Cooperation with USound to Explore Advanced Sensing Technologies for Next-Generation Wearable Devices
2 hours ago

ZenoWell Announces Strategic Cooperation with USound to Explore Advanced Sensing Technologies for Next-Generation Wearable Devices

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions